Canada’s Ontario Institute for Cancer Research (OICR) has announced investments in three new Ontario companies aimed at bringing promising anticancer technologies to market.
“The establishment of these innovative companies will help bring commercial and operational leadership that will accelerate the development and market acceptance of their promising assets,” said Frank Stonebanks, vice president, commercialization, and chief commercial officer of the OICR. “With early translational research, seed capital and professional management, OICR is committed to supporting the most promising new approaches to fighting cancer.”
“The anticancer technologies developed by these companies offer hope for improved health outcomes for people in Ontario and around the world who are fighting cancer,” said Glen Murray, Ontario Minister of Research and Innovation. “These three companies represent the best in Ontario innovation and are creating high-quality jobs with world-class researchers in this province.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze